Navigation Links
Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:12/15/2010

EAST BRUNSWICK, N.J., Dec. 15, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 11:00 a.m. Pacific Time.  The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.  

A live webcast of the presentation and the question and answer session can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017 Zymo Research Corp., also known as ,The Epigenetics Company, ... aging in a precise manner using the myDNAge ™ test. Based ... professor of human genetics and biostatistics at the David Geffen School ... , Zymo Research,s proprietary DNAge ™ technology is used to analyze ... ...
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 2017 , ... “Nana Nana Boo Boo”: a delightful tale of a young ... Nana Boo Boo” is the creation of published author Michael Rush, a Deputy Sheriff, ... Publishing, Michael Rush’s new book presents the importance of manners in a way easily ...
(Date:7/24/2017)... , ... July 24, 2017 , ... “Journey to the ... odyssean novel that details a young woman’s path to finding herself. “Journey to ... creation of published author, Jamie Grayson, an experienced writer of newsletters, manuals, and articles, ...
(Date:7/23/2017)... Virginia (PRWEB) , ... July 24, 2017 , ... ... the American Association of Physicists in Medicine (AAPM) 59th Annual Meeting & Exhibition, ... Members of the medical physics profession, hospital administrators and journalists can visit the ...
(Date:7/23/2017)... ... July 23, 2017 , ... A 20-year-long study ... and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports growing evidence ... offers very few benefits. , In the cases involved with this study, surgery ...
(Date:7/23/2017)... ONTARIO, CANADA (PRWEB) , ... July 23, 2017 ... ... effects of single sport specialization is critical, say researchers presenting their work today ... in Toronto, Canada. , “Our study is the first one to prospectively ...
Breaking Medicine News(10 mins):